{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Gramlich M"],"funding":["European Research Council"],"pagination":["562-76"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4492817"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["7(5)"],"pubmed_abstract":["Frameshift mutations in the TTN gene encoding titin are a major cause for inherited forms of dilated cardiomyopathy (DCM), a heart disease characterized by ventricular dilatation, systolic dysfunction, and progressive heart failure. To date, there are no specific treatment options for DCM patients but heart transplantation. Here, we show the beneficial potential of reframing titin transcripts by antisense oligonucleotide (AON)-mediated exon skipping in human and murine models of DCM carrying a previously identified autosomal-dominant frameshift mutation in titin exon 326. Correction of TTN reading frame in patient-specific cardiomyocytes derived from induced pluripotent stem cells rescued defective myofibril assembly and stability and normalized the sarcomeric protein expression. AON treat"],"journal":["EMBO molecular medicine"],"pubmed_title":["Antisense-mediated exon skipping: a therapeutic strategy for titin-based dilated cardiomyopathy."],"pmcid":["PMC4492817"],"funding_grant_id":["261053"],"pubmed_authors":["McGaughran J","Thierfelder L","Gawaz MP","Zhou Q","Moretti A","Labeit S","Laugwitz KL","Metzger K","Schaller M","Pane LS","Atherton JJ","Sinnecker D","Mann M","Brade T","Gramlich M","Chen Z","Gerull B","Harvey RP","Parrotta E","Murgia M","Aartsma-Rus A","Schotterl S","Goedel A"],"additional_accession":[]},"is_claimable":false,"name":"Antisense-mediated exon skipping: a therapeutic strategy for titin-based dilated cardiomyopathy.","description":"Frameshift mutations in the TTN gene encoding titin are a major cause for inherited forms of dilated cardiomyopathy (DCM), a heart disease characterized by ventricular dilatation, systolic dysfunction, and progressive heart failure. To date, there are no specific treatment options for DCM patients but heart transplantation. Here, we show the beneficial potential of reframing titin transcripts by antisense oligonucleotide (AON)-mediated exon skipping in human and murine models of DCM carrying a previously identified autosomal-dominant frameshift mutation in titin exon 326. Correction of TTN reading frame in patient-specific cardiomyocytes derived from induced pluripotent stem cells rescued defective myofibril assembly and stability and normalized the sarcomeric protein expression. AON treat","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 May","modification":"2026-04-30T14:03:48.142Z","creation":"2019-03-27T01:54:38Z"},"accession":"S-EPMC4492817","cross_references":{"pubmed":["25759365"],"doi":["10.15252/emmm.201505047"]}}